Paul Chretien
Neurodevelopmental Disabilities · Sacramento, CANPI 1972615227
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 181 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Tris Pharma Inc at 31.6% of the total.
Across 181 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tris Pharma Inc$1K
- UCB, Inc.$533
- Novartis$389
- Supernus Pharmaceuticals, Inc.$305
- Greenwich Biosciences, Inc.$300
- Sunovion Pharmaceuticals Inc.$233
- plus $833 from 16 others
What the payments were for
- Food & beverage$3,791100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tris Pharma Inc | 17 | $1,197 |
| UCB, Inc. | 26 | $533 |
| Novartis | 13 | $389 |
| Supernus Pharmaceuticals, Inc. | 22 | $305 |
| Greenwich Biosciences, Inc. | 13 | $300 |
| Sunovion Pharmaceuticals Inc. | 41 | $233 |
| Neos Therapeutics, LP | 12 | $173 |
| Ironshore Pharmaceuticals Inc. | 9 | $130 |
| Livanova USA, Inc. | 4 | $79 |
| Eisai Inc. | 5 | $78 |
| Mallinckrodt Enterprises LLC | 3 | $76 |
| Aquestive Therapeutics, Inc. | 3 | $51 |
| PTC Therapeutics, Inc. | 2 | $42 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 2 | $40 |
| Vertical Pharmaceuticals, LLC | 2 | $37 |
| Sarepta Therapeutics, Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Travere Therapeutics, Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $18 |
| Biomarin Pharmaceutical Inc. | 1 | $17 |
| Promius Pharma LLC | 1 | $16 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quillivant XR$488
- Dyanavel XR$247
- Briviact$225
- Epidiolex$140
- AFINITOR$121
- GILENYA$106
How this compares
$3,791 in reported general payments places this provider in the 65th percentile of 21 neurodevelopmental disabilities providers in California.
See all neurodevelopmental disabilities providers in California →
Other neurodevelopmental disabilities in Sacramento
- William ShieldsLos Angeles$5.9M
- Raman SankarLos Angeles$1.1M
- Joyce WuLos Angeles$23K
- Ying PengLadera Ranch$18K
- Jason LernerLos Angeles$11K
- Elysa MarcoSan Francisco$10K
- Christopher GizaLos Angeles$7K
- Sabrina CarterSanta Barbara$2K
- Anuja JindalSan Diego$1K
- Rebecca GarfinkleLaguna Niguel$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.